FCGR2B and autoimmune thrombocytopenic purpura: Evidence from a murine model of immune thrombocytopenia suggests that the molecular basis of IVIG treatment is its ability to induce expression of the inhibitory Fcγ receptor (FcγRIIB) on macrophages and thus prevent platelet consumption (39).